<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02966080</url>
  </required_header>
  <id_info>
    <org_study_id>1609884386</org_study_id>
    <nct_id>NCT02966080</nct_id>
  </id_info>
  <brief_title>Fixed Low-dose Heparin Versus Standard Adjusted-dose Heparin Infusion in Adults Receiving Venovenous ECMO With a Heparin Bonded Circuit.</brief_title>
  <official_title>Fixed Low-dose Heparin Versus Standard Adjusted-dose Heparin Infusion in Adults Receiving Venovenous Extracorporeal Membrane Oxygenation (ECMO) With a Heparin Bonded Circuit.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heparin is a blood thinner used to prevent blood clots in patients on a form of life-support
      called ECMO. Heparin can cause bleeding - the most common complication of ECMO. New materials
      used in ECMO machines may help prevent clots - this could allow the use of lower doses of
      heparin which might reduce the risk of bleeding. Our study will compare low dose to high dose
      heparin in patients on ECMO. We think low dose heparin may be adequate to prevent clotting,
      but may cause less bleeding and be safer for patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravenous heparin is considered standard therapy to prevent clotting complications in
      patients on ECMO, however the optimal method of heparin dosing has not yet been determined.
      International surveys have shown that most ECMO centers use adjusted dose heparin to achieve
      an activated clotting time of at least 180 seconds. However, heparin may contribute to the
      most common complication of ECMO - bleeding. Advances in material technology have potentially
      reduced the thrombogenicity of modern ECMO circuits. Our observational data suggest that
      fixed low dose heparin infusion may reduce the rate of bleeding complications from 75% to 50%
      compared to standard adjusted-dose heparin, without increasing clotting complications. We
      intend to perform a randomized controlled trial in adults receiving venovenous ECMO comparing
      these two heparin regimens. The main outcome measures are bleeding complications and
      oxygenator failure due to clotting. A safety committee will monitor the results of the study.
      Power calculations indicate a sample size of 110 patients is required, which we estimate will
      take us five years to achieve.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No participants enrolled, study will not be conducted.
  </why_stopped>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>significant bleeding complications</measure>
    <time_frame>intraoperative</time_frame>
    <description>requires surgery, &gt;1 unit packed blood cell transfusion or is intracranial, pulmonary or retroperitoneal</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxygenator failure</measure>
    <time_frame>intraoperative</time_frame>
    <description>Requirement to replace oxygenator due to clotting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebral vascular event (stroke)</measure>
    <time_frame>intraoperative</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acute Respiratory Failure</condition>
  <condition>Extracorporeal Membrane Oxygenation Complication</condition>
  <condition>Bleeding</condition>
  <arm_group>
    <arm_group_label>Adjusted-dose heparin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in this arm of the study will receive intravenous unfractionated heparin at a dose adjusted to achieve an activated clotting time of 180-200 seconds.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fixed low-dose heparin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in this arm of the study will receive intravenous unfractionated heparin at 500 units/hour without activated clotting time monitoring.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HEP-IV</intervention_name>
    <arm_group_label>Adjusted-dose heparin</arm_group_label>
    <arm_group_label>Fixed low-dose heparin</arm_group_label>
    <other_name>heparin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  on ECMO for acute respiratory failure, achieving ECMO blood flow rate &gt;3L/min,

          -  patient or surrogate able to speak/understand English or Spanish

        Exclusion Criteria:

          -  History of heparin-induced thrombocytopenia, decision by clinicians to run ECMO off
             heparin due to high bleeding risk,

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Raschke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Banner - University Medical Center Phoenix</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner - University Medical Center Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.elso.org</url>
    <description>ELSO anticoagulation guideline</description>
  </link>
  <reference>
    <citation>Esper SA, Levy JH, Waters JH, Welsby IJ. Extracorporeal membrane oxygenation in the adult: a review of anticoagulation monitoring and transfusion. Anesth Analg. 2014 Apr;118(4):731-43. doi: 10.1213/ANE.0000000000000115. Review.</citation>
    <PMID>24651227</PMID>
  </reference>
  <reference>
    <citation>Poulos EM, Raschke R, Amabile O et al. A Nonrandomized comparison of three different heparin infusion strategies for patients receiving venovenous extracorporeal membrane oxygenation. Am J Respir Crit Care Med 2014;189: A4499.</citation>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2016</study_first_submitted>
  <study_first_submitted_qc>November 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2016</study_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Arizona</investigator_affiliation>
    <investigator_full_name>Robert Raschke</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>extracorporeal membrane oxygenation</keyword>
  <keyword>intravenous heparin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

